Personalised Cancer Plan
Make treatment decisions with greater confidence
Precision insights that complement standard oncology care to guide next-step planning and ongoing monitoring.
Clinical Efficacy
Precision-guided personalised plans have shown measurable benefits across studies — including better tumour response, longer time without worsening, and improved outcomes in high-risk or hard-to-treat cancers.
Longer time without worsening
Weeks without disease worsening in advanced cancers.
Improved response in hard cases
Higher response when therapies are combined and personalised.
High-risk paediatric outcomes
2-year progression-free survival improvement reported in high-risk paediatric cancers.
Long-term survival trend
Survival rates across cancers have improved over decades. Advances in diagnostics, targeted therapies, and precision approaches have contributed to this progress.
Evidence summary
Precision-guided treatment in high-risk pediatric cancers
Functional precision medicine in relapsed / refractory pediatric cancers
WINTHER trial: genomic + transcriptomic profiling
Combination precision therapies improve outcomes in cancer
Clinical benefit of precision approach in refractory cancers
Study details (tap to expand)
Precision-guided treatment in high-risk pediatric cancers
2024
- Response rate around 36% in studied high-risk pediatric cases.
- 2-year no-worsening 26% compared with 12%.
- Supports decision-making in difficult pediatric oncology settings.
Functional precision medicine for relapsed / refractory pediatric cancers
2024
- No-worsening improved up to 83% in evaluated cases.
- Highlights the value of functional approaches in relapsed disease.
WINTHER trial: genomic + transcriptomic profiling
2019
- Stable disease or better in ~26% with guided selection.
- Demonstrates value of integrating genomic + transcriptomic signals.
Combination precision therapies improve outcomes in cancer
2019
- Response 50% vs 22% with combination and personalised strategies.
- Supports combining precision selection with multi-agent planning.
Clinical benefit of precision approach for refractory cancers
2016
- Clinical benefit 43% vs 5% compared with unmatched approaches.
- No-worsening time 86 vs 49 days.
- Highlights value in hard-to-treat refractory cancers.
Talk to our team to understand how precision insights may support treatment planning.
Book a 15-Minute Consultation with our Cancer Professionals
This consultation will help you understand how precision medicine may support your treatment journey.
Contact Us
Contact Us for the updated information on Precision Medicine
+852 4750 3485
Email Us
info@mycancerinfo.org